Find the right fit for you - faster
Get tailored insights about working at Vir Biotechnology in one quick step.
Vir Biotechnology Snapshot
We are a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Infectious diseases are one of the leading causes of death worldwide and the cause of hundreds of billions of dollars of economic burden each year. We believe that now is the time to apply the recent and remarkable advances in immunology to combat infectious diseases. Our approach begins with identifying the limitations of the immune system in combating a particular pathogen, the vulnerabilities of that pathogen and the reasons why previous approaches have failed. We then bring to bear powerful technologies that we believe, individually or in combination, will lead to effective therapies.
We are taking a multi-program, multi-technology platform approach, assembled through internal development, collaborations, and acquisitions.
We have an industry-leading management team, board of directors and scientific advisors with significant experience in immunology and infectious diseases, and with progressing product candidates from early stage research to clinical trials, regulatory approval and ultimately commercialization.
Guided by science, we relentlessly build on our immunologic expertise and technologies in pursuit of transformative medicines for infectious diseases. Our innovations stem from courage and bold ideas. We approach each day with a sense of optimism and humility, recognizing that our strength resides in the diversity of our journeys and the opportunity to learn from each other.
We are taking a multi-program, multi-technology platform approach, assembled through internal development, collaborations, and acquisitions.
We have an industry-leading management team, board of directors and scientific advisors with significant experience in immunology and infectious diseases, and with progressing product candidates from early stage research to clinical trials, regulatory approval and ultimately commercialization.
Guided by science, we relentlessly build on our immunologic expertise and technologies in pursuit of transformative medicines for infectious diseases. Our innovations stem from courage and bold ideas. We approach each day with a sense of optimism and humility, recognizing that our strength resides in the diversity of our journeys and the opportunity to learn from each other.
Vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. Vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. The company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
